Condition: Premature Infant · Low Birthweight Infant · Sponsor: Société des Produits Nestlé (SPN)
The goal of this post-market study is to describe the effect of a liquid supplement containing 2 specific human milk oligosaccharides (HMOs), 2'-fucosyllactose \[2'FL\] and lacto-N-neotetraose \[LNnT\], on feeding tolerance, growth, and adverse events of special interest in preterm infants in a real-world setting. A comparison with data collected retrospectively from a historical group at each site will be made for time to reach full enteral feeding, growth and adverse events. Infants in the historical group were not exposed to an HMO supplement but followed the same local nutrition protocol to avoid confounding by differences in clinical or feeding practice.
This description comes directly from the study's public registry record.
Inez Sroda · +41217858259 · Inez.Sroda@rd.nestle.com
Always discuss trial participation with your own doctor first.
| Kepler Universitätsklinikum Linz | Linz, Austria | Recruiting |
| Evangelisches Waldkrankenhaus Spandau | Berlin-Spandau, Germany | Recruiting |
| Kinderklinik Darmstadt | Darmstadt, Germany | Recruiting |
| Wilhelmstift Hamburg | Hamburg, Germany | Withdrawn |
| Uniklinik Heidelberg | Heidelberg, Germany | Recruiting |
| Klinikum Nürnberg | Nuremberg, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06212427